<DOC>
	<DOC>NCT02062203</DOC>
	<brief_summary>The main purpose of this study is to evaluate the effect of single oral therapeutic and supratherapeutic doses of AKB-6548 on the QT interval.</brief_summary>
	<brief_title>Effect of AKB-6548 on Cardiac Repolarization Intervals in Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
	<criteria>Key Healthy, nonsmoking males or females, 18 and 55 years of age, inclusive BMI 18.0 and 32.0 kg/m2, inclusive non clinically significant 12lead ECG heart rate of 45 to 90 beats per minute, inclusive mean systolic blood pressure &lt;141 mmHg and mean diastolic blood pressure &lt; 90 mmHg Key history or presence of significant cardiovascular, pulmonary, hepatic, renal, hematologic, GI, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease history of unexplained syncope, cardiac arrest, unexplained cardiac arrhythmias, or torsades de pointes, structural heart disease, or a family history of Long QT syndrome significant abnormalities in liver function tests history of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs history of Gilbert's Syndrome positive hepatitis panel seizure disorder or receiving antiepilepsy medication for seizure disorder any acute or chronic condition that, in the opinion of the Investigator, may pose a safety risk to a subject in this study or which would limit the subject's ability to complete and/or participate in this clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Akebia</keyword>
	<keyword>QT interval</keyword>
	<keyword>TQT</keyword>
	<keyword>pharmacokinetic</keyword>
	<keyword>anemia</keyword>
	<keyword>chronic kidney disease</keyword>
	<keyword>CKD</keyword>
	<keyword>chronic renal insufficiency</keyword>
	<keyword>renal impairment</keyword>
	<keyword>safety</keyword>
</DOC>